Chronic kidney disease screening to reduce cardiovascular risk: a call to action
American Journal of Preventive Cardiology · 2026-02 · 25 · 101380
DOI: 10.1016/j.ajpc.2025.101380 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Preventive Cardiology, 2026-02. Verfasst von Erin D Michos und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Blalock 524-B, 600 N Wolfe Street, Baltimore, MD 21287, …. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Boehringer Ingelheim.
Abstract (Originalsprache)
Chronic kidney disease (CKD) has a high global prevalence, affecting around 1 in 7 adults in the United States; however, most adults with CKD are unaware that they have the condition. Diagnosis and treatment of CKD is essential due to the associated increased morbidity and mortality, including increased risk of cardiovascular disease (CVD) and heart failure. Importantly, people with CKD are more likely to die from CVD than progress to end-stage kidney disease. Dual evaluation of estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR) is essential to determine the level of risk and to guide appropriate treatment. Although abnormalities in both eGFR and UACR can be modifiable risk factors for CKD progression and adverse CV outcomes, there is evidence of underuse of this dual screening for CKD. However, for patients with diagnosed CKD, striking reductions in cardiorenal risk may be achieved by combining appropriate evidence-based therapies. Current approaches to management of CKD involve the use of multiple therapies that target different pathological pathways to reduce cardiorenal risk. Therefore, we raise a call to action to improve the standard of care for early diagnosis and management of CKD, to minimize the risk of disease progression and complications, reduce CV risk, and ultimately improve patient outcomes. Alongside primary care clinicians, cardiologists can also lead the way for preventive efforts and implementation of guideline-directed therapies that can reduce the risk of both CKD progression and adverse CV outcomes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Blalock 524-B, 600 N Wolfe Street, Baltimore, MD 21287, USA.
- Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, 585 University Ave, 8N-845, Toronto, Ontario M5G 2N2, Canada.
- Department of Family Medicine, University of California at Irvine, 1001 Health Sciences Road, Irvine, CA 92697, USA.
Förderung
- Boehringer Ingelheim
Zitieren
APA
Michos, E. D., Cherney, D., & Kushner, P. (2026). Chronic kidney disease screening to reduce cardiovascular risk: a call to action. American Journal of Preventive Cardiology, 25, 101380. https://doi.org/10.1016/j.ajpc.2025.101380
Vancouver
Michos ED, Cherney D, Kushner P. Chronic kidney disease screening to reduce cardiovascular risk: a call to action. American Journal of Preventive Cardiology. 2026;25:101380. doi:10.1016/j.ajpc.2025.101380
BibTeX
@article{Michos2026,
author = {Michos, Erin D and Cherney, David and Kushner, Pam},
title = {Chronic kidney disease screening to reduce cardiovascular risk: a call to action},
journal = {American Journal of Preventive Cardiology},
year = {2026},
volume = {25},
pages = {101380},
doi = {10.1016/j.ajpc.2025.101380}
}
EUVIMED